Finnish pharmaceutical company Orion Corporation (HEL:ORNBV) and Invenra Inc, a biotechnology company with proprietary technologies for discovering novel therapeutics, on Thursday announced a research collaboration and licensing agreement focused on developing bispecific antibody cancer therapeutics.

The agreement leverages Invenra's B-Body platform for bispecific antibody discovery.

Invenra will manage the process from monoclonal antibody discovery to optimised bispecific lead panels, and Orion will select targets and assume responsibility for development, manufacturing and global commercialisation.

The agreement grants Orion commercial licences for up to two bispecific antibodies.

This partnership unites Invenra's expertise in bispecific antibody engineering with Orion's pharmaceutical development capabilities. The collaboration aims to create innovative therapeutic solutions for cancer.